IMV (NYSE:IMV) released its quarterly earnings results on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.03), MarketWatch Earnings reports. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.05 million.
NYSE:IMV traded down $0.30 on Friday, hitting $2.58. 8,241 shares of the stock were exchanged, compared to its average volume of 19,864. IMV has a 52 week low of $2.25 and a 52 week high of $7.07. The company’s 50-day moving average price is $2.74 and its 200 day moving average price is $3.15.
A number of research analysts recently issued reports on IMV shares. HC Wainwright set a $11.50 price target on IMV and gave the company a “buy” rating in a report on Monday, September 30th. Zacks Investment Research cut IMV from a “buy” rating to a “hold” rating in a report on Saturday, October 26th. Wells Fargo & Co started coverage on IMV in a report on Monday, October 28th. They issued a “market perform” rating for the company. Finally, Raymond James set a $10.00 price objective on IMV and gave the stock an “outperform” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $8.94.
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Recommended Story: Why does the United States have a lingering trade deficit?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.